RamamoorthyNagasubramanianMD

Pediatric Hematology & Oncology • Orlando, FL

Chief, Division of Pediatric Hematology-Oncology

Join to view full profile

Dr. Nagasubramanian is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Nagasubramanian's full profile

Already have an account?

Office
13535 Nemours Parkway
Suite 100
Orlando, FL 32827
Phone+1 407-650-7230

Fax+1 407-650-7233
Is this information wrong?

Education & Training

University of ChicagoFellowship, Pediatric Hematology/Oncology, 2000 - 2002
University of ChicagoFellowship, Pediatric Hematology/Oncology, 1995 - 1998
University of ChicagoResidency, Pediatrics, 1993 - 1995
Kilpauk Medical CollegeClass of 1988

Certifications & Licensure

TX State Medical License 2006 - Present
AZ State Medical License 2024 - 2026
FL State Medical License 1996 - 2025
CA State Medical License 2023 - 2025
IL State Medical License 1993 - 2008
MI State Medical License 1997 - 1998
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Start of enrollment: 2001 Feb 01
Unknown status
Phase 3
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Active, not recruiting
Phase 3
Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma Start of enrollment: 2004 Mar 15
Completed
Phase 3
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Start of enrollment: 2004 Sep 04
Completed
Phase 3
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Start of enrollment: 2004 Mar 25
Recruiting
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Start of enrollment: 2004 Apr 01
Active, not recruiting
Phase 3
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Start of enrollment: 2005 Nov 14
Completed
Phase 3
Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission Start of enrollment: 2005 May 30
Completed
Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer Start of enrollment: 2006 Feb 20
Completed
Phase 3
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Start of enrollment: 2007 May 03
Completed
Phase 3
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Start of enrollment: 2006 Jun 01
Completed
Phase 2
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Start of enrollment: 2007 Aug 06
Active, not recruiting
Phase 3
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Start of enrollment: 2006 Oct 30
Active, not recruiting
Phase 3
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Start of enrollment: 2006 Dec 26
Completed
Phase 3
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Start of enrollment: 2007 Mar 01
Completed
Phase 3
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Start of enrollment: 2007 Mar 01
Completed
Phase 1, Phase 2
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Start of enrollment: 2007 Feb 26
Active, not recruiting
Phase 3
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Start of enrollment: 2007 Mar 01
Completed
Phase 3
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET Start of enrollment: 2007 Mar 26
Active, not recruiting
Phase 3
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Start of enrollment: 2007 Jan 22
Active, not recruiting
Phase 3
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia Start of enrollment: 2007 Jan 01
Completed
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin Start of enrollment: 2007 May 01
Completed
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia Start of enrollment: 2008 Jan 01
Completed
Phase 2
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Start of enrollment: 2008 Feb 04
Active, not recruiting
Phase 3
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Jan 15
Active, not recruiting
Phase 3
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System Start of enrollment: 2008 Dec 08
Active, not recruiting
Phase 3
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Start of enrollment: 2008 Apr 01
Completed
Phase 2
Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers Start of enrollment: 2008 Jun 02
Completed
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Start of enrollment: 2008 Jun 23
Completed
Phase 3
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Start of enrollment: 2008 Jul 17
Recruiting
Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
Recruiting
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2009 Jan 01
Completed
Phase 2
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia Start of enrollment: 2009 Mar 09
Completed
Phase 3
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Start of enrollment: 2009 Mar 01
Completed
Phase 2
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2006 Sep 25
Completed
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
Completed
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Recruiting
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma Start of enrollment: 2008 Feb 04
Completed
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma Start of enrollment: 2008 Feb 04
Completed
Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma Start of enrollment: 2006 Oct 23
Completed
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 1999 Mar 15
Completed
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Start of enrollment: 2004 Feb 16
Completed
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13
Active, not recruiting
Phase 3
Study of Blood Samples From Newborns With Down Syndrome Start of enrollment: 2009 Feb 23
Completed
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 3
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma Start of enrollment: 2005 May 30
Completed
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Start of enrollment: 2010 Jan 01
Completed
Phase 2
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
Active, not recruiting
Phase 3
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Start of enrollment: 2011 Feb 01
Completed
Phase 2
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Start of enrollment: 2010 Oct 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Start of enrollment: 2010 Nov 22
Active, not recruiting
Phase 3
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Start of enrollment: 2011 Apr 04
Completed
Phase 3
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Start of enrollment: 2011 May 01
Completed
Not Applicable
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Start of enrollment: 2011 Sep 01
Completed
Phase 3
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor Start of enrollment: 2011 Aug 01
Completed
Phase 2
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Start of enrollment: 2012 Jan 01
Completed
Phase 2
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission Start of enrollment: 2012 Feb 21
Active, not recruiting
Phase 3
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients Start of enrollment: 2012 Jun 01
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas Start of enrollment: 2013 Jun 17
Active, not recruiting
Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant Start of enrollment: 2013 Nov 04
Completed
Phase 3
Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer Start of enrollment: 2013 Oct 01
Withdrawn
Phase 2
Molecular Phenotyping of Asthma in Sickle Cell Disease Start of enrollment: 2011 Jun 01
Completed
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Start of enrollment: 2017 Nov 29
Recruiting
Phase 3
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2019 Jul 08
Active, not recruiting
Phase 2
Topical Rapamycin/Sirolimus for Complicated Vascular Anomalies and Other Susceptible Lesions Start of enrollment: 2020 Apr 01
Recruiting
Phase 1
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Start of enrollment: 2020 Apr 06
Active, not recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1 citations
Comparison of variants in TPMT and NUDT15 between sequencing and genotyping methods in a multistate pediatric institution.
Kelsey J Cook, Victoria Grusauskas, Lucy Gloe, Benjamin Q Duong, Renee C Gresh, E Anders Kolb, Manisha Bansal, Allison S Bechtel, Ramamoorthy Nagasubramanian, Susan M ...> ;Clinical and Translational Science. 2023 Aug 1
Symptom management care pathway adaptation process and specific adaptation decisions.
Emily Vettese, Farha Sherani, Allison A King, Lolie Yu, Catherine Aftandilian, Christina Baggott, Vibhuti Agarwal, Ramamoorthy Nagasubramanian, Kara M Kelly, David R F...> ;BMC Cancer. 2023 Apr 17
488 citations
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong, Steven G. DuBois, Shivaani Kummar, Anna F. Farago, Catherine M. Albert, Kristoffer Staal Rohrberg, Cornelis M. van Tilburg, Ramamoorthy Nagasubramanian,...> ;The Lancet. Oncology. 2020 Apr 1
A Survival Analysis of Pediatric Tonsillar Malignancies and Review of a Rare Case.
Tyler A. Janz, Ramamoorthy Nagasubramanian, Julie L. Wei> ;International Journal of Pediatric Otorhinolaryngology. 2019 Mar 1
6 citations
Pediatric head and neck fibrosarcomas: A demographical, treatment, and survival analysis and review of a rare case
Tyler A. Janz, Ramamoorthy Nagasubramanian, Julie L. Wei> ;International Journal of Pediatric Otorhinolaryngology. 2019 Jan 1
89 citations
The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
Steven G. DuBois, Theodore W. Laetsch, Noah Federman, Brian Turpin, Catherine M. Albert, Ramamoorthy Nagasubramanian, Megan E. Anderson, Jessica L. Davis, Hope Qamoos,...> ;Cancer. 2018 Nov 1
333 citations
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Theodore W. Laetsch, Steven G. DuBois, Leo Mascarenhas, Brian Turpin, Noah Federman, Catherine M. Albert, Ramamoorthy Nagasubramanian, Jessica L Davis, Erin R. Rudzins...> ;The Lancet. Oncology. 2018 May 1
1530 citations
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar, Steven G. DuBois, Ulrik Lassen, George D. Demetri, Michael J. Nathenson, Robert C. Doebele, Anna F. Farago, Alb...> ;The New England Journal of Medicine. 2018 Feb 21
6 citations
Targeting NTRK fusions for the treatment of congenital mesoblastic nephroma
Theodore W. Laetsch, Ramamoorthy Nagasubramanian, Michela Casanova> ;Pediatric Blood & Cancer. 2018 Jan 1
267 citations
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Alexander Drilon, Ramamoorthy Nagasubramanian, James F. Blake, Nora Ku, Brian B. Tuch, Kevin Ebata, Steve Smith, Veronique Lauriault, Kolakowski Gabrielle R, Barbara J...> ;Cancer Discovery. 2017 Sep 1
82 citations
Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Ramamoorthy Nagasubramanian, Julie Wei, Paul Gordon, Jeffrey C. Rastatter, Michael C. Cox, Alberto S. Pappo> ;Pediatric Blood & Cancer. 2016 Aug 1
3 citations
The Current State of Imaging Pediatric Hemoglobinopathies
David Dinan, Monica Epelman, Carolina V. Guimaraes, Lane F. Donnelly, Ramamoorthy Nagasubramanian, Nancy A. Chauvin> ;Seminars in Ultrasound, CT, and MR. 2013 Dec 1
106 citations
Genetic predictors for stroke in children with sickle cell anemia
Jonathan M. Flanagan, Denise M. Frohlich, Thad A. Howard, William H. Schultz, Catherine Driscoll, Ramamoorthy Nagasubramanian, Nicole A. Mortier, Amy C. Kimble, Banu A...> ;Blood. 2011 Jun 16
4 citations
The Werner’s syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds
Federico Innocenti, Snezana Mirkov, Ramamoorthy Nagasubramanian, Jacqueline Ramírez, Wanqing Liu, Wasim K. Bleibel, Sunita J. Shukla, Kathleen A. Hennessy, Gary L. Ros...> ;Cancer Chemotherapy and Pharmacology. 2009 Apr 1
3 citations
Survival and tumorigenesis in O6-methylguanine DNA methyltransferase-deficient mice following cyclophosphamide exposure
Ramamoorthy Nagasubramanian, Ryan J. Hansen, Shannon M. Delaney, Mathew M. Cherian, Leona D. Samson, Scott C. Kogan, M. Eileen Dolan> ;Mutagenesis. 2008 Sep 1
31 citations
Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice.
Ryan J. Hansen, Ramamoorthy Nagasubramanian, Shannon M. Delaney, Leona D. Samson, M. Eileen Dolan> ;Carcinogenesis. 2006 Nov 20
8 citations
Role of O6-Alkylguanine-DNA Alkyltransferase in Protecting against 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-Induced Long-Term Toxicities
Ryan J. Hansen, Ramamoorthy Nagasubramanian, Shannon M. Delaney, Mathew M. Cherian, Shang Lin, Scott C. Kogan, M. Eileen Dolan> ;The Journal of Pharmacology and Experimental Therapeutics. 2005 Dec 1
89 citations
Heritability and Linkage Analysis of Sensitivity to Cisplatin-Induced Cytotoxicity
M. Eileen Dolan, Karla G. Newbold, Ramamoorthy Nagasubramanian, Xiaolin Wu, Mark J. Ratain, Edwin H. Cook, Judith A. Badner> ;Cancer Research. 2004 Jun 15
84 citations
Pharmacogenetics in cancer treatment
Ramamoorthy Nagasubramanian, Federico Innocenti, Mark J. Ratain> ;Annual Review of Medicine. 2003 Nov 28
30 citations
Temozolomide: realizing the promise and potential.
Nagasubramanian R, Dolan Me> ;Current Opinion in Oncology. 2003 Nov 1
Join now to see all

Journal Articles

Pediatric Head and Neck Fibrosarcomas: A Demographical, Treatment, and Survival Analysis and Review of a Rare Case
Ramamoorthy Nagasubramanian, Tyler A Janz, Julie L Wei, ScienceDirect

Press Mentions

Potential Drug for Tumors in Childhood and Adult Cancers FoundFebruary 22nd, 2018
Cancer Survivors Must Make Decisions on Fertility IssuesDecember 6th, 2015